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ABSTRACT 
An Assessment of Gadonanotubes as Magnetic Nanolabels for Improved 
Stem Cell Detection and Retention in Cardiomyoplasty 
by 
Lesa A. Tran 
In this work, gadolinium-based carbon nanocapsules are developed as a novel 
nanotechnology that addresses the shortcomings of current diagnostic and therapeutic 
methods of stem cell-based cardiomyoplasty. With cardiovascular disease (CVD) 
responsible for approximately 30% of deaths worldwide, the growing need for improved 
cardiomyoplasty has spurred efforts in nanomedicine to develop innovative techniques to 
enhance the therapeutic retention and diagnostic tracking of transplanted cells. Having 
previously been demonstrated as a high-performance T1-weighted magnetic resonance 
imaging (MRI) contrast agent, Gadonanotubes (GNTs) are shown for the first time to 
intracellularly label pig bone marrow-derived mesenchymal stem cells (MSCs). Without 
the use of a transfection agent, micromolar concentrations of GNTs deliver up to 
10
9
 Gd
3+
 ions per cell, allowing for MSCs to be visualized in a 1.5 T clinical MRI 
scanner. The cellular response to the intracellular incorporation of GNTs is also assessed, 
revealing that GNTs do not compromise the viability, differentiation potential, or 
phenotype characteristics of the MSCs. However, it is also found that GNT-labeled 
MSCs exhibit a decreased response to select cell adhesion proteins and experience a non-
apoptotic, non-proliferative cell cycle arrest, from which the cells recover 48 h after GNT 
internalization. In tandem with developing GNTs as a new stem cell diagnostic agent, this 
  
current work also explores for the first time the therapeutic application of the 
magnetically-active GNTs as a magnetic facilitator to increase the retention of 
transplanted stem cells during cardiomyoplasty. In vitro flow chamber assays, ex vivo 
perfusion experiments, and in vivo porcine injection procedures all demonstrate the 
increased magnetic-assisted retention of GNT-labeled MSCs in the presence of an 
external magnetic field. These studies prove that GNTs are a powerful ‘theranostic’ agent 
that provides a novel platform to simultaneously monitor and improve the therapeutic 
nature of stem cells for the treatment of CVD. It is expected that this new nanotechnology 
will further catalyze the development of cellular cardiomyoplasty and other stem cell-
based therapies for the prevention, detection, and treatment of human diseases. 
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Chapter 1 
Introduction 
Although stem cell therapy has proven to be an effective approach to treat 
cardiovascular disease (CVD), the challenges of improving the therapeutic retention and 
diagnostic visualization of transplanted stem cells remain unsolved. This work, for the 
first time, presents the superparamagnetic gadolinium-based carbon nanocapsules known 
as Gadonanotubes (GNTs) as a nanotechnological platform with simultaneous therapeutic 
and diagnostic, or theranostic, capabilities that help solve the limitations of current 
cardiovascular stem cell therapeutic methods. 
With CVD as the leading cause of death worldwide, interest in cell transplantation 
therapy, or cardiomyoplasty, to treat damaged cardiac tissue has grown exponentially 
over the past decade. Of the various cell types used for cardiomyoplasty, adult bone 
marrow-derived mesenchymal stem cells (MSCs) are particularly attractive for clinical 
use because of their allogeneic nature, therapeutic potential, and ease of isolation and 
expansion. As such, numerous preclinical and clinical studies in recent years have 
 16 
suggested the effective performance of transplanted MSCs in repairing damaged 
cardiovascular tissue. Irrespective of the cell type used, however, the low rates of cell 
homing, retention, and survival in the heart are fundamental challenges that must be 
overcome to enhance the therapeutic outcome of current cell transplantation approaches. 
Another inherent shortcoming of cardiomyoplasty is the difficulty in noninvasively 
tracking the movement of transplanted cells to elucidate their biodistribution and eventual 
incorporation into cardiac tissue. For these reasons, recent research efforts in 
nanotechnology and nanomedicine have focused on the development of innovative tools 
and methods to improve the therapeutic efficiency and diagnostic imaging of transplanted 
cells.
1–3
 Having previously been demonstrated as a high-performance T1-weighted 
magnetic resonance imaging (MRI) contrast agent with efficacies over 40 times higher 
than currently available clinical agents, the magnetically-active GNTs have the potential 
to address the limitations of stem cell therapy, as documented and discussed in this thesis. 
To fully illustrate the background and significance of this work, Chapter 2 reviews the 
biology of MSCs, the current status of stem cell therapy, and the recent developments of 
GNTs as a clinical MRI agent.  
In this thesis, the primary objective is to evaluate the efficiency of GNTs as an 
intracellular MRI nanolabel. Chapter 3 details the in vitro optimization of GNT cell 
labeling, electron microscopy imaging of the intracellular GNT retention, and MRI 
visualization of GNT-labeled MSCs using a clinical 1.5 T MRI scanner. After the 
successful demonstration of T1-weighted MR imaging of GNT-labeled MSCs, the short- 
and long-term cellular response to the intracellular incorporation of GNTs is assessed 
before advancing to in vivo experiments. In Chapter 4, the assays and transcriptome 
 17 
analysis evaluating the effects of GNT incorporation on MSC viability, differentiation 
potential, adhesion behavior, phenotype characteristics, and growth kinetics are 
presented. Sections of Chapters 3 and 4 have been drawn from previously published work 
by L.A. Tran et al.
4
 Along with developing GNTs as an intracellular MRI agent, the 
magnetically-active GNTs are presently being evaluated as a magnetic facilitator to 
improve the retention of GNT-labeled MSCs in cardiac tissue during cardiomyoplasty. 
Chapter 5 describes for the first time the in vitro, ex vivo, and in vivo experiments 
demonstrating the magnetically-driven therapeutic application and retention efficiency of 
GNT-labeled MSCs. Finally, Chapter 6 summarizes the conclusions of the described 
studies and elaborates on the future work envisioned beyond this present work to further 
confirm the potential of GNTs as a new, powerful stem cell theranostic agent for the 
treatment of CVD.  
 18 
 
 
 
Chapter 2 
Background and Literature Review 
2.1. Mesenchymal Stem Cells 
MSCs are nonhematopoietic multipotent progenitor cells found in all mammals 
that have the ability to differentiate into a variety of mesenchymal lineages, including 
adipocytes, chondrocytes, osteocytes, and cardiomyocytes. Although extremely rare in 
bone marrow (approximately 1:100,000), MSCs can readily be isolated and expanded in 
vitro by more than 1 million-fold while retaining their growth and multilineage potential.
5
 
Similar to fibroblastic cell lines, MSCs expand at a fast rate but maintain their contact 
inhibition upon reaching confluence in culture.  
Phenotypically, MSCs express a number of cell surface markers, including CD29, 
CD90, CD105; however, none are specific to MSCs and the expression levels of these 
markers are heavily influenced by the tissue source, isolation methods, and in vitro 
conditions.
6
 It is also established that MSCs do not express hematopoietic markers, such 
 19 
as CD45, or the endothelial marker CD31.
7
 MSCs also produce an array of growth factors 
and cytokines which can induce surrounding endogenous cells through a paracrine 
mechanism to differentiate while the MSCs undergo new tissue formation.  
One striking characteristic that has been observed is that at appropriate levels, the 
presence of cultured MSCs does not stimulate immune responses within in vivo systems, 
due to their lack of major histocompatibility complexes and co-stimulatory molecules and 
their ability to secrete immunosuppressive cytokines.
8
 Therefore, it may be possible to 
isolate MSCs from one donor, expand them in vitro, and administer them to an allogeneic 
host without the need for immunosuppression. Additionally, MSCs have the natural 
ability to home to sites of injury and inflammation, which suggest their active role in 
tissue repair.
9
 This homing property is independent of the distance of the MSCs from the 
injury site, but diminishes with age and disease. 
 
2.2. Stem Cell Cardiomyoplasty 
Because of their ease of isolation and in vitro expansion, differentiation potential, 
paracrine effects, immunologic characteristics, and homing abilities, MSCs are ideal 
candidates for regenerative therapies to treat disorders of the bone, muscle, vasculature, 
organs, and skin.
10
 In particular, recent studies have evaluated the use of MSCs for the 
treatment of cardiac injury after acute myocardial infarction (AMI) and chronic heart 
failure (CHF).  A meta-analysis performed by Abdel-Latif et al. on 999 patient cases in 
18 small clinical trials concluded that the use of adult bone marrow cells, such as MSCs, 
as therapeutic agents for cardiac repair post-AMI and CHF is safe and associated with 
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more anatomical and functional improvements than that of conventional therapies.
11
 
Similar cardiomyoplasty studies performed using MSCs in porcine models corroborated 
the benefits of stem cell transplantation, suggesting that implanted MSCs in damaged 
myocardium improved postinfarction hemodynamics and prevented wall thinning and 
stiffness.
12
 
Despite the positive yet modest outcomes of MSC-based cardiomyoplasty, two 
major challenges still need to be addressed in the development of this therapy. One issue 
is the low and variable rates of cell retention and survival in the heart, which greatly 
limits the success of restoring cardiac tissue and function. Using immunohistochemistry 
and radiolabeling techniques, several studies based on human and animal models have 
reported that between 5-15% of the MSCs remain in the heart post-transplantation with 
the majority of the cells traveled to other organs in the body, regardless of the delivery 
method and dosage level used.
13–16
 Several biochemical and physical approaches have 
been explored to improve the retention and survival of transplanted cells in the 
myocardium, including transgenic enhancement of protein secretion, in vitro conditioning 
for improved survival function, exploitation of endogenous mechanisms to enhance 
homing, biochemical targeting of tissue-specific cues,
17
 and transplantation of cells 
integrated in biomaterials or as three-dimensional (3D) aggregates to enhance cell 
differentiation and function.
18,19
 However, clinical translation of such methods may be 
difficult to scale up and only moderately improved rates have been observed. 
Another major drawback in stem cell therapy is the difficulty to accurately and 
noninvasively track MSCs in real-time and determine the eventual biodistribution of the 
cells post-transplantation. While many imaging modalities and labeling agents have been 
 21 
explored (MRI of magnetic particles, γ imaging of radiolabels, neutron activation of 
lanthanide-based compounds, and optical imaging of quantum dots and fluorescent 
reporter genes), these methods have moderate efficacies and the agents used must be in 
high concentrations to be detectable, which introduces the risk of becoming cytotoxic to 
the cells.
16,20,21
 The visualization of individual cells and their tissues requires that each 
molecule of a particular agent induce a sufficient signal intensity to be detected at low 
concentrations, since biological constraints limit the amount of molecules that can be 
delivered into a single cell to the nanomolar (nM) range at a given time.
22
 
To simultaneously resolve the issues of low retention rates and noninvasive cell 
tracking, the magnetic targeting and MRI of cells labeled with magnetic particles can be 
employed. However, no one to date has concurrently studied the magnetic-assisted 
retention and MRI visualization of magnetically-labeled cells for cardiomyoplasty. Cheng 
et al. have recently demonstrated that magnetic targeting enhances the engraftment and 
functional performance of superparamagnetic microsphere (SPM)-labeled cardiosphere-
derived cells (CDCs) when intramyocardially transplanted into the infracted hearts of 
rats.
23,24
 Using a superimposed magnet at the injection site, magnetic targeting enhanced 
the retention and eventual engraftment of iron-labeled CDCs in the recipient hearts by 
approximately 3-fold when compared to non-targeted cells over a 3-week period. 
However, these studies did not explore the MRI visualization of SPMs, which are larger 
versions (900 nm) of the FDA-approved superparamagnetic iron oxide (SPIO) 
nanoparticles (50-150 nm) used as T2-weighted MRI contrast agents (CAs). Although 
proven moderately effective, T2-weighted CAs generally darken acquired magnetic 
resonance (MR) images which may not be ideal for enhancing visual details (as opposed 
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to T1-weighted CAs that brighten MR images). Nonetheless, SPIO nanoparticles have 
been shown to be internalized by MSCs, unlike the T1-weighted Gd
3+
-based MRI CA 
Magnevist®.
25
 To optimize cellular uptake, most researchers employ the use of 
polycationic transfection agents such as protamine sulfate and poly-L-lysine (PLL). It has 
been demonstrated that the internalization of low dosages of SPIO nanoparticles does not 
affect cell viability or proliferation, but the use of a transfection agent may affect MSC 
differentiation.
26
 Additionally, many polydisperse polycationic transfection agents are not 
FDA-approved for clinical use, as they are cytotoxic when used alone or at high (10 
µg/mL) concentrations.
27,28
   
 
2.3. Gadonanotubes 
Carbon nanostructures are ideal platforms for medical therapeutic and diagnostic 
agent design.
29
 The two main categories of these materials are carbon fullerenes (C60, C70, 
C80, C2n, etc.), which are spherical carbon molecules, and carbon nanotubes (CNTs), 
which are cylindrical rolls of graphene sheets. Because their surfaces can be chemically 
modified, carbon nanostructures may serve as molecular scaffolds for medically-relevant 
moieties such as drugs, peptides, antibodies, and other functional groups.
30
 This surface 
functionalization may allow carbon nanostructures to become nontoxic, 
nonimmunogenic, and water-soluble.
31–33
 In addition to being bioinert,
34
 carbon 
nanostructures have also been shown to translocate across cellular membranes and 
accumulate within cells without significant cytotoxic effects.
4,35–37
 Finally, the empty 
space within carbon nanostructures allows for the encapsulation of small molecules and 
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ions.
38–40
  This loading ability is particularly useful in the design of MRI CAs, as these 
carbon nanomaterials can trap Gd
3+
 ions within the carbon cage and prevent the metal 
ions from dissociating under physiological conditions, thus producing 
gadonanostructures.
41
  
 
Figure 2.1 – Representative illustrations of two gadonanostructures: (a) a 
Gadofullerene and (b) a Gadonanotube. 
Two gadonanostructures (Figure 2.1) that have recently been evaluated as T1-
weighted MRI CAs are the Gadofullerenes and GNTs. Gadofullerenes (GFs) are 
endohedral C60 fullerenes that encase a single Gd
3+
 ion inside the carbon framework, 
while GNTs are short (20-80 nm) segments of single-walled CNTs (SWNTs) that 
encapsulate small clusters of 5-10 Gd
3+
 ions.
29
 Gadonanostructures have been reported to 
exhibit T1 relaxivities of up to 40 times higher than those of MRI CAs in current clinical 
use. The GFs have r1 values ranging from 20 to 100 mM
-1
 s
-1
 (37 °C, 1.5 T).
33
 More 
impressively, the GNTs hold the highest recorded relaxivity to date at a clinically-
relevant field, with a value of 170 mM
-1
 s
-1
 (37 °C, 1.5 T).
42
  
0.70 nm
1.4 nm
(a) (b)
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Although both gadonanostructures exhibit higher T1 relaxivities when compared 
to current MRI CAs, the GNTs are superior to the GFs from a synthetic standpoint.  
Because the production of GFs is both chemically challenging and time-consuming, 
obtaining large quantities of GFs is extremely difficult.
29
 However, the synthesis of 
GNTs requires far less effort to produce gram quantities, which may be critical if the 
widespread clinical use of GNTs is ever to be realized. This ease of production is due to 
their ability to internally load Gd
3+
 ions through the many sidewall defects produced by 
the chemical cutting procedure used to produce GNTs.
42
  
It has been demonstrated that GNTs can serve as effective cellular magnetic 
probes. Due to their short length, GNTs can readily internalize into mammalian cells 
without the assistance of a transfection agent. As suggested by Raffa et al., short CNTs 
(similar to GNTs) coated in surfactant can act as tiny ‘nano-needles’ that can insert and 
readily diffuse through cellular membranes.
43
 As such, recent studies have shown that 
GNTs can internalize into a variety of cell types, performing as an effective T1-weighted 
CA in breast cancer cells
37
 and T2-weighted CA in macrophages.
44
 This phenomenon, in 
addition to their inherent magnetic properties, biocompatibility, and relaxivity 
performance, has prompted a more extensive investigation of GNTs as a new cellular 
labeling platform to improve MRI contrast at lower dosages. 
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Chapter 3 
Gadonanotubes as MRI Nanolabels for Stem 
Cell Detection 
3.1. Introduction 
The demand for advanced cell tracking technologies is increasing in the field of 
stem cell therapy. While currently relying on the immunohistochemistry of extracted 
tissue samples to visualize cells within a living system, investigators desire a noninvasive 
and more accurate means of imaging transplanted stem cells in vivo to better examine 
their regenerative abilities, monitor their retention rate in the target tissue, and determine 
the biodistribution of cells post-transplantation.  
Recent efforts have been made to develop nanoparticle-based stem cell labeling 
techniques using MRI.
20,35,45,46
 Among the various medical diagnostic imaging modalities 
available, MRI is ideal for tracking stem cells in vivo as it allows for serial imaging 
acquisitions that provide high spatial resolution in a noninvasive and non-ionizing 
manner. In 2007, approximately 43% of the 27.5 million clinical MRI procedures 
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performed in the U.S. use CAs to alter MR signals.
47
 In general, paramagnetic T1-
weighted CAs, which enhance MR signals to produce bright positive contrast, are 
preferred over superparamagnetic T2-weighted CAs, which decrease MR signals to 
produce dark negative contrast. The hypointensity caused by T2-weighted CAs may make 
it more difficult to distinguish them from the inherently low signals caused by other 
tissues or imaging artifacts.
48
 Most available T1-weighted CAs are based on the Gd
3+
 ion 
because of its high magnetic moment and symmetric electronic ground state.
49
 However, 
these FDA-approved gadolinium-based CAs (GBCAs) are restricted to extracellular 
space and, in general, lack the ability to accumulate within cells to produce signal 
intensity enhancement for their detection on the cellular level.
50
  
A primary focus in GBCA advancement is the development of new CAs that 
exhibit greater water-proton relaxation efficacy, or relaxivity, than that of current CAs to 
improve image contrast. Because biological constraints limit the number of CAs that can 
be delivered to the surface or interior of a single cell to the nanomolar (nM) range at a 
given time,
22
 the visualization of individual cells and tissues requires that each unit of a 
particular CA produce a high enough signal intensity to be detected at nanomolar 
concentrations. In addition to its performance, an ideal CA must also be biologically inert 
and biocompatible at appropriate dosage levels for clinical use. To address these 
concerns, the high-performance GNTs were examined as an intracellular MRI agent that 
can effectively label cells at low loading concentrations. This chapter describes the in 
vitro cell labeling performance of GNTs in pig bone marrow-derived MSCs for T1-
weighted cellular MRI. 
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3.2. Materials & Methods 
3.2.1. Synthesis of Gadonanotubes 
GNTs were produced by following a previously established protocol.
42
 Briefly, 
full-length SWNTs synthesized by the electric-arc discharge method were cut into ultra-
short SWNTs (US-tubes, 20-80 nm in length) by fluorination followed by pyrolysis at 
1000 °C under an inert Ar atmosphere.
51
 After production, the US-tubes were sonicated 
with concentrated HCl for 60 min to remove metal catalyst impurities. The US-tubes 
were then reduced using Na
0
/THF to produce predominantly individualized, or 
debundled, US-tubes.
52
 Next, the US-tubes were refluxed in 6 N HNO3 until boiling for 5 
min and washed repeatedly with deionized water to pH 7.0. To load the US-tubes with 
Gd
3+
 ions, the debundled US-tubes were bath sonicated in an aqueous, acidic GdCl3 
solution (1 mg/mL, pH 3) for 60 min. The solution was left undisturbed overnight to 
allow for the gadolinium-loaded US-tubes (GNTs) to flocculate out of solution. Upon 
discarding the supernatant, the flocculated GNTs were collected by filtration, washed 
repeatedly with deionized water to remove excess external Gd
3+
 ions, and dried at 60 °C. 
Biocompatible solutions of GNTs were made by suspending dry GNTs in 0.17% 
(w/v) Pluronic F-108 surfactant (BASF Corporation; Florham Park, NJ, USA) via probe 
sonication for 5 min, followed by centrifugation at 3200 rpm for 10 min to remove 
unsuspended GNTs. For all studies, the Gd
3+
-ion concentration of GNT solutions was 
maintained at 76 µM, as confirmed by inductively-coupled plasma-optical emission 
spectrometry (ICP-OES). Prior to their addition to cell cultures, GNT solutions were 
sterilized under UV light while rocking for 3 h. 
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3.2.2. Cell Culture 
MSCs were harvested and isolated from the bone marrow of male pigs as 
described elsewhere.
53
 MSCs were expanded in two successive passages at 2×10
3
 
cells/cm
2
. Cells in the second passage (P2) were then frozen in cryovials, and at 
appropriate times, MSCs were thawed and expanded once (P3) prior to labeling. Cell 
cultures were incubated at 37 °C (95% relative humidity in 5% CO2). Unless otherwise 
specified, MSCs were grown and maintained in alpha minimal essential medium 
(αMEM) containing 10% fetal bovine serum (FBS) and 1% antibiotic supplement 
(200mM L-glutamine, 10,000 units/mL penicillin, and 10 mg/mL streptomycin). All 
labeling studies were performed with P3 MSCs. 
 
3.2.3. Label Concentration 
To determine the optimal labeling concentration, MSCs were initially plated on 6-
well tissue culture plates at 2×10
4
 cells/well and were allowed to reach 70% confluence. 
The medium was removed, and the attached cells were co-cultured with GNTs in αMEM 
at various Gd
3+ 
ion concentrations (15-42 µM). After 24 h, the cells were washed with 
phosphate buffered saline (1×PBS) and exposed to a mild ice-cold acid-strip buffer 
solution (50 mM glycine-HCl, 100 mM NaCl, and 2 mg/mL polyvinylpyrrolidone at pH 
3.0) for 10 min at 4 °C. This has been previously shown to remove up to 95% of 
membrane-bound ligands without affecting cell viability.
54
 The cells were washed again 
with 1×PBS and lifted upon exposure to trypsin-EDTA for 5 min. The cell suspension of 
GNT-labeled MSCs was then passed through a 70 µm nylon filter to eliminate large cell-
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GNT aggregates and transferred to a 50 mL conical tube. To isolate “cleaned” cells 
(GNT-labeled MSCs without GNTs on their cellular membranes) from excess GNTs in 
solution, a density gradient centrifugation method was performed. Briefly, Histopaque® 
1077 (25 °C, Sigma-Aldrich; St. Louis, MO, USA) was slowly added to the bottom of the 
tube at a 1:2 volume ratio (Histopaque:cells). The sample was then centrifuged at 400×g 
for 20 min. Upon successful separation, GNT-labeled MSCs were located at the interface 
of the αMEM and Histopaque phases. These cells were then isolated and washed twice 
with 1×PBS and centrifuged at 1500 rpm for 10 min. (Light microscopy images of the 
cells during the cleaning protocol are documented in Figure A1 in Appendix A) The cells 
were counted (Beckman Coulter MultiSizer 3) and prepared for ICP-OES analysis. 
 
3.2.4. Incubation Time 
MSCs were plated and grown as described above. The medium was removed, and 
the cells were co-cultured with GNTs (27 µM Gd
3+) in αMEM. The cells were then 
incubated and collected at various times (1, 2, 4, 8, 12, and 24 h). Upon collection, cells 
were processed as described above and prepared for ICP-OES analysis. 
 
3.2.5. Cell Viability 
MSCs were labeled with GNTs (27 µM Gd
3+
) for 24 hours and collected as 
described above. Positive controls (unlabeled MSCs) and negative controls (unlabeled 
MSCs treated with 70% methanol for 30 min) were also cultured. A LIVE/DEAD® 
viability/cytotoxicity assay kit (Life Technologies; Grand Island, NY, USA) was used to 
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determine the viability of the GNT-labeled MSCs. The LIVE/DEAD reagents consist of 
calcein AM, which fluoresces green upon being cleaved from esterase activity in viable 
cells, and ethidium homodimer-1, which fluoresces red and can only enter cells with a 
compromised cellular membrane. To each well, the LIVE/DEAD reagents were added 
and the culture plates were incubated in the dark at RT for 30 min. Fluorescence-
activated cell sorting (BD Excalibur Flow Cytometer) was used to measure fluorescence 
intensities. 
 
3.2.6. Label Retention 
MSCs were plated and grown as previously mentioned above. A pulse-chase 
protocol was then performed on the MSCs, which includes cell labeling in αMEM 
containing GNTs (27 µM Gd
3+
) for 24 h (pulse) and replacing the incubating medium 
with fresh αMEM without GNTs (chase). Two experimental groups were examined: in 
Group A, the culture medium remained unchanged for the entire chase time; in Group B, 
the medium was changed every 24 h during the entire chase time (72 h). The cells and 
culture media were separately collected at 24, 48, and 72 h after initiating the chase and 
were prepared for ICP-OES analysis. 
 
3.2.7. Electron Microscopy 
MSCs were grown on 175 cm
2
 cell culture flasks, incubated with GNTs (27 µM 
Gd
3+
) in αMEM for 0.5, 2, 6, 12, or 24 h, and collected. Separate populations of GNT-
labeled MSCs were replated in fresh αMEM without GNTs and were collected at 24, 48, 
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and 72 h. Unlabeled MSCs were also grown as a control group. Once collected, all cell 
populations (2×10
5
 each sample) were separately prepared and centrifuged at 1500 rpm 
for 10 min to form cell pellets. The cell pellets were fixed in 4% glutaraldehyde for 2 
days, washed with 1×PBS, post-fixed with 1% OsO4 for 1 h, dehydrated through a series 
of graded alcohol washes, infiltrated with acetone and Epon 812 plastic resin, and 
embedded with 100% Epon 812 in a mold. Several 1 µm sections (thick sections) were 
cut and stained with 1% methylene blue and 1% basic fuchsin. Ultra-thin sections (80 
nm) were cut from the sample block using an RMC MTXL ultra microtome and mounted 
on 100-mesh copper grids. The grids were stained with 2% alcoholic uranyl acetate and 
Reynold’s lead citrate. The samples were examined with a JEOL 1250 TEM at 60 kV and 
equipped with an AMTV 540 digital imaging system at St. Luke’s Episcopal Hospital 
(Houston, TX). 
 
3.2.8. Magnetic Resonance Imaging 
For pellet samples, unlabeled and GNT-labeled MSCs were separately prepared 
and centrifuged into cell pellets in Eppendorf tubes at 10×10
6
 cells/tube with 1 mL 
αMEM. Another cell pellet of MSCs incubated in αMEM with Magnevist® 
(Gadopentetic acid; Gd-DTPA; 27 µM Gd
3+
) for 24 h was also prepared. A 1.5 T MRI 
scanner (Achieva; Philips Health Care, The Netherlands) was used for the in vitro cellular 
MRI studies at room temperature (RT; 25 °C). A transmit-receive head coil was used for 
the acquisitions. An inversion recovery prepared turbo-spin sequence was used to 
measure the T1 relaxation times of the samples (TR = 2500 ms; TE = 13 ms). The 
acquisition matrix resolution was 0.5 × 0.5 × 2.5 mm acquired over a field-of-view of 45 
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× 45 mm. Acquisitions were made at 8 different inversion times (TI) from 50-2200 ms 
and T1 was calculated using the standard inversion recovery equation. 
 
3.2.9. Elemental Analysis 
ICP-OES analyses were performed by a PerkinElmer Optima 4300 DV 
Inductively-Coupled Plasma-Optical Emission Spectrometer. Five scans were performed 
for each sample. Gadolinium concentration was detected at 342.247 nm, while yttrium 
(371.029 nm) was used as the internal drift standard. To prepare samples for analysis, the 
collected cell samples were transferred to glass scintillation vials and heated with 500 µL 
25% HClO3 until boiling. Once the samples turned from yellow to colorless, an 
additional aliquot of HClO3 was added and heated to evaporation. The samples were then 
diluted to 10 mL with 2% trace-metal HNO3 and filtered through a 0.22 µm syringe filter. 
 
3.2.10. Statistical Analysis 
Unless otherwise noted, all experiments were conducted in triplicate. Results are 
presented as mean ± SEM. Statistical analysis between any two groups in the in vitro 
rolling assay was performed using a two-tailed paired Student’s t test. Differences were 
considered statistically significant when p < 0.05.  
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3.3. Results & Discussion 
3.3.1. Cell Labeling 
Optimal conditions were determined for the magnetic labeling of MSCs with 
GNTs. Figure 3.1a shows cellular uptake as a function of GNT concentration. The most 
efficient labeling concentration was found to be at 27 µM Gd
3+
, which delivered up to 
0.98 pg or approximately 10
9
 Gd
3+
 ions per cell, without affecting cell viability (98% 
based on calcein AM-positive cells, LIVE/DEAD assay; Figure A2 in the Appendix A). 
Complete labeling was achieved by 4 h and remained constant for up to 24 h of 
incubation, as shown in Figure 3.1b. Similar GNT labeling efficiencies were observed for 
other mammalian cell types, including breast cancer cells
37
 and macrophages.
44
 Although 
this labeling method is an effective way to intracellularly deliver large quantities of metal 
ions, its results are still considered conservative when compared to other nanoparticle-
based labeling techniques. For example, a recent study recorded up to 20 pg of magnetite 
cationic liposomes, or approximately 10
11
 Fe atoms, were internalized per human MSC 
after 4 h.
55
 Similarly, Gd
3+
-ion encapsulated C60 fullerenes (Gd@C60) internalized up to 
133.6 pg, or 10
11
 Gd
3+
 ions, per mouse MSC within 2-8 h of incubation.
35
 However, a 
direct comparison cannot be made between the present GNT-MSC system and other 
nanoparticle-based MSC labeling studies, since cellular uptake is highly dependent on the 
type of nanoparticle used, their preparation, and their administration to cell cultures.
56
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Figure 3.1 – MSC uptake of GNTs as a function of (a) GNT concentration and (b) 
incubation time. These graphs are plotted on a logarithmic scale. Note: error bars 
may be smaller than symbols. 
Transmission electron microscopy (TEM) visually confirmed the progression of 
GNT cellular uptake, as depicted in Figure 3.2. As opposed to what is seen in unlabeled 
MSCs (Figure 3.2a), GNTs appear as irregular electron-dense aggregates within the 
cytoplasm of MSCs as early as 0.5 h of labeling time. There is no clear indication of 
GNTs transported into the nucleus. In the early stages of the GNT labeling process 
(Figure 3.2b-d), TEM images provide evidence of both vesiculated and nonvesiculated 
GNT aggregates. This observation suggests that GNTs can enter MSCs by either direct 
membrane penetration or by active endocytosis, both of which have been observed for the 
internalization of multi-walled CNTs (MWNTs) into human embryonic kidney epithelial 
cells.
57
 However, the GNT aggregates found at 12 and 24 h (Figure 3.2e-f) seem to be too 
large to be enclosed by any vesicular membrane, which is typically 5 nm in thickness.
58
  
(a) (b)
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Figure 3.2 – TEM images of (a) unlabeled MSCs and MSCs labeled with GNTs for 
(b) 0.5 h, (c) 2 h, (d) 6 h, (e) 12 h, and (f) 24 h. Red arrows point to GNT aggregates. 
Scale bar = 2 µm. 
In a separate study, GNT-labeled MSCs were replated in fresh αMEM and 
collected at 24, 48, and 72 h to examine the intracellular movement of the GNT 
aggregates after labeling.  As seen in Figure 3.3a and b, large GNT aggregates are still 
(a) (b)
(c) (d)
(e) (f)
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apparent 48 h after labeling.  However, the aggregates have migrated towards the cellular 
membrane at 72 h (Figure 3.3c), suggesting that exocytosis of the GNTs may ultimately 
occur. Based on these results, GNTs are retained by the MSCs for up to 72 h after 
labeling. However, a more in-depth study detailing the uptake and eventual release of the 
GNTs from the cells and the intracellular mechanism of these processes is warranted. 
 
Figure 3.3 – TEM images of GNT-labeled MSCs after (a) 24 h, (b) 48 h, and (c) 72 h. 
Red arrows point to GNT aggregates. Scale bar = 2 µm. 
3.3.2. Label Retention 
In addition to understanding their mechanism of uptake, the eventual release of 
GNTs from cells must be considered. To determine whether the GNTs “leak” from the 
MSCs over time, a pulse-chase study was performed (Figure 3.4). The Gd
3+
-ion content 
of the GNT-labeled cells and their culture medium were analyzed under two different 
experimental conditions. In one set (Group A, gray), no medium changes were performed 
during the entire chase period (72 h), while in a second set (Group B, black), the medium 
was replaced every 24 h during the chase period. As seen in Figure 3.4a and b, a decrease 
(a) (b) (c)
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in Gd
3+
-ion content in the cell samples occurred at 24 h but remained unchanged in both 
groups for up to 72 h. Conversely, an increase in Gd
3+
-ion content in the media samples 
was observed after chasing for 24 h. This initial loss of Gd
3+
-ion content from the cell 
samples into the media is likely due to the removal of residual GNTs from the cellular 
membrane of the MSCs. However, the quantity of Gd
3+
 ions in the media of Group B 
decreased to an undetectable level by 72 h upon replenishing the media every 24 h, while 
the quantity found in the media of Group A remained unchanged. 
 
Figure 3.4 – GNT retention in MSCs as a function of chase time: (a) the total 
average number of Gd
3+
 ions found in the cell samples, (b) the total average number 
of Gd
3+
 ions in the media, (c) the total average number of Gd
3+
 ions per GNT-
labeled cell, and (d) the cell count of each cell sample upon collection. All graphs are 
plotted on a logarithmic scale. Note: error bars may be smaller than the symbols; * 
indicates  p < 0.05 for Group B when compared to Group A. 
(a) (b)
(c) (d)
*
*
*
*
*
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To better understand the dynamics of GNTs within the cell cultures and whether 
MSCs retain GNTs for up to 72 h after having been labeled, the average number of Gd
3+
 
ions internalized per cell in each group was calculated (Figure 3.4c) based on the cell 
population of each group over time (Figure 3.4d). From these calculations, it is seen that 
the average number of Gd
3+
 ions per cell for Groups A and B remained constant between 
24 and 48 h of chase time, as the cell populations remained static in an extended growth 
lag phase (when compared to the proliferation rate of unlabeled MSCs). This stunted cell 
growth phase suggests that the Gd
3+
 ion content detected in the media may be attributed 
to natural cell death and/or cell detachment 24-48 h after labeling. However, the 
quantification of dead cells in the media during the chase period proved to be difficult, 
since cell debris was mostly observed. 
A significant decrease in Gd
3+
 ion content per cell was observed only for Group B 
after 72 h of chase time. This observed loss in Gd
3+
 ion content may be attributed to 
either (1) an active release of GNTs from the cells, which would lead to a respective 
increase of GNT content in the media samples, or (2) cell proliferation, which would 
divide each culture’s total GNT content by a larger cell number and therefore lower the 
average number of Gd
3+
 ions on a per cell basis. GNT-labeled MSCs from both groups 
exhibited increased growth rates after 48 h, which implies that the cells eventually 
adjusted to the presence of the foreign GNT nanoparticles. Additionally, Group B 
proliferated faster than Group A, suggesting that changing the media, hence removing 
dead GNT-labeled cells and replenishing nutrients, results in a healthier environment that 
promoted cell growth. This accelerated proliferation rate corresponded to a decrease in 
Gd
3+
 ion content on a per cell basis at 72 h. The undetectable amount of Gd
3+
 ions in the 
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media at 72 h also suggests that no significant loss of intracellular Gd
3+
 ion content by the 
active cellular release of GNTs occurred. The Gd
3+
 ion content in each cell remained high 
even after 72 h, with approximately 10
8
 Gd
3+
 ions per cell in both Groups A and B. 
Although the above results suggest that the loss of Gd
3+
 ions into the media over 
time is more likely due to cell death and cell detachment rather than to the movement of 
GNTs across cellular membranes, the release of GNTs from the cells may still possibly 
occur. Because it is crucial to ensure the GNT-labeled cells lack membrane-bound GNTs, 
an extensive cell cleaning and separation protocol was used for these studies; however, 
the initial Gd
3+
-ion loss from the cells after chasing for 24 h suggests that the cleaning 
method used is not completely effective in removing all excess GNTs from the cell 
exteriors. Additionally, the eventual release of GNTs from MSCs due to cell death and 
their eventual redistribution could impact their performance as in vivo magnetic labeling 
agents and therefore should be further studied. 
 
3.3.3. Magnetic Resonance Imaging Detection 
To simulate the number of MSCs in a single injection that will be delivered for 
the treatment of acute myocardial infarction,
15
 MR images were taken of GNT-labeled 
MSCs, Gd-DTPA-labeled MSCs, and unlabeled MSCs (10×10
6
 MSCs/pellet) at various 
inversion delay (Ti) times (Figure 3.5). Substantial MR signal contrast was generated 
between the labeled and the unlabeled cells. The T1 of GNT-labeled MSCs was 494.9 ms 
(95%, 378-610 ms), the T1 of Gd-DTPA-labeled MSCs was 1079 ms (CB: 95%, 698-
1461 ms), and the T1 of unlabeled MSCs was 875.9 ms (CB: 95%, 595-1157 ms).  
 40 
 
Figure 3.5 – T1-weighted MR images at 1.5 T and 25 °C of (left to right) unlabeled 
MSCs, Gd-DTPA-labeled MSCs, and GNT-labeled MSCs at TI = (a) 150 ms, (b) 300 
ms, (c) 500 ms, and (d) 800 ms. 
With a nearly two-fold decrease in the measured T1 relaxation time of GNT-
labeled MSCs compared to unlabeled MSCs, the GNTs serve as effective in vitro 
magnetic labeling agents, even at low loading concentrations. In comparison to Gd-
DTPA, which did not label cells at all under the same conditions, GNTs produced a 
significant contrast enhancement. However, several challenges still need to be addressed 
for in vivo MRI, such as longer relaxation times and lower contrast produced by tissues, 
the presence of imaging artifacts, and the inherently low sensitivity of clinical MRI 
scanners to image on the cellular level. Regardless, the significant T1 reduction of GNT-
labeled MSCs and the lack of cytotoxicity of the GNTs make these carbon nanostructures 
serious candidates as MRI cell labeling agents for in vivo cell monitoring studies. 
(a) (b)
(c) (d)
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Chapter 4 
Cellular Response to the Intracellular 
Incorporation of Gadonanotubes 
4.1. Introduction 
Although GNTs have been shown to effectively label MSCs without 
compromising cell viability, further assessment of the short- and long-term cellular 
behavior of GNT-labeled MSCs must be completed before GNTs can be considered for 
clinical use. Since their regenerative properties, differentiation potential, and 
immunologic characteristics make MSCs attractive candidates for cellular 
cardiomyoplasty, these functional properties must be retained after the cells have 
internalized the GNTs. However, the response of mammalian cells to the intracellular 
incorporation of CNTs is not well-understood and highly disputed, primarily because the 
cellular effects observed are highly dependent on the cells examined and the type, length, 
surface chemistry, and purity of the CNTs used.
59–61
 While SWNTs and MWNTs have 
been shown to inhibit proliferation and differentiation of MSCs
62
 and induce oxidative 
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stress and apoptosis in vitro,
59,63–65
 other studies have indicated that CNTs are nontoxic 
and do not adversely affect the behavior of cells and animals.
66–69
  
Because of the inconsistent results found among the various toxicological reports 
on CNTs, a comprehensive study investigating the cellular response of MSCs to GNT 
internalization is required. More importantly, it must be established whether GNT-labeled 
MSCs retain their regenerative properties and are suitable for therapeutic applications 
after having been exposed to GNTs. This chapter reports for the first time a functional 
and genomic profiling of GNT-labeled MSCs, with a focus on cell phenotype and 
differential potential, growth kinetics, cell adhesion, and effects on cell cycle 
mechanisms. 
 
4.2. Materials and Methods 
4.2.1. Cell Culturing and Labeling 
MSCs were harvested and isolated from the bone marrow of male pigs as 
described elsewhere.
53
 MSCs were expanded in two successive passages at 2×10
3
 
cells/cm
2
. Cells in the second passage (P2) were then frozen in cryovials, and at 
appropriate times, MSCs were thawed and expanded once (P3) prior to labeling. Cell 
cultures were incubated at 37 °C (95% relative humidity in 5% CO2). Unless otherwise 
specified, MSCs were grown and maintained in alpha minimal essential medium 
(αMEM) containing 10% fetal bovine serum (FBS) and 1% antibiotic supplement 
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(200mM L-glutamine, 10,000 units/mL penicillin, and 10 mg/mL streptomycin). All 
labeling studies were performed with P3 MSCs. 
Three cell populations were cultured and used in the subsequent studies: (1) GNT-
labeled MSCs, (2) Pluronic-treated MSCs, and (3) unlabeled MSCs. Unless otherwise 
noted, GNT-labeled MSCs were prepared, processed, and collected as earlier described in 
Section 3.2.3. For transcriptome analyses, the GNT-labeled MSCs used were prepared in 
the following manner: after incubation with GNTs (27 µM Gd
3+
) for 24 h, MSCs were 
washed three times with 1×PBS and lifted upon exposure to trypsin-EDTA for 5 min. 
The cell suspension of GNT-labeled MSCs was then passed through a 70 µm nylon filter 
to eliminate large cell-GNT aggregates. For Pluronic-treated MSCs, cells were incubated 
in 0.17% Pluronic F-108 in αMEM (35% v/v) for 24 h, washed three times with 1×PBS, 
and lifted upon exposure to trypsin-EDTA for 5 min. The cell suspension was then 
passed through a 70 µm nylon filter to eliminate large cell aggregates. 
 
4.2.2. Phenotyping of Cell Surface Markers 
Unlabeled and GNT-labeled MSCs were labeled with FITC mouse anti-pig CD45 
primary antibody (clone K252-1E4; AbD Serotec, Oxford, UK), PECy5 mouse anti-
human CD90 (clone 5E10, BD Pharmingen), FITC mouse anti-human CD105 (clone 
MEM-229; Abcam), and FITC mouse anti-pig CD29 primary antibody (cloneNaM160-
1A3, BD Pharmingen). Data acquisition was performed on a FACS Calibur Flow 
Cytometer (Becton Dickinson). Unlabeled and GNT-labeled MSCs were analyzed for the 
expression of various factors, including CD29, CD45, CD90, and a secondary antibody. 
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4.2.3. Cell Differentiation 
GNT-labeled MSCs were grown under adipogenic, osteogenic, or chondrogenic 
conditions for 14-21 days to evaluate their differentiation potential. The differentiation of 
positive controls (unlabeled MSCs exposed to differentiation conditions) and negative 
controls (unlabeled MSCs exposed to only αMEM) were also prepared and monitored. 
For adipogenic differentiation, GNT-labeled MSCs were plated and grown in 6-
well tissue culture plates at 2×10
4
 cells/well. Once 70% confluence was reached, the cells 
were first grown in adipogenic differentiation medium (10 µg/mL insulin, 10% FBS, 1 
µM dexamethasone, 0.5 mM methyl-isobutylxanthine, and 100 µM indomethacine in 
high glucose DMEM) for 3 days and then grown in adipogenic maintenance medium (10 
µg/mL insulin and 10% FBS in high glucose DMEM) for another 3 days. This alternating 
treatment was repeated twice more to obtain full adipogenic differentiation. The 
adipogenic cultures were stained with Oil Red O, which identifies the presence of lipid 
vacuoles within the MSCs. 
For osteogenic differentiation, GNT-labeled MSCs were plated and grown in 6-
well tissue culture plates at 3×10
4
 cells/well. Once 70% confluence was reached, the cells 
were cultured in osteogenic differentiation medium (10% FBS, 50 μg/mL ascorbate 2 
phosphate, 0.1 μM dexamethasone, and 10 mM β-glycerol phosphate in high glucose 
DMEM) for 21 days, with media replacement every 3-4 days. Upregulated alkaline 
phosphatase activity, a characteristic of early osteocytes, was observed in GNT-labeled 
MSCs upon staining the cultures with a Vector Red Alkaline Phosphatase Substrate Kit 
(Vector Laboratories, Inc.; Burlingame, CA, USA) with a fluorescent microscope. 
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For chondrogenic differentiation, 2×10
5
 GNT-labeled MSCs were transferred into 
15-mL conical tubes and centrifuged at 450 rpm for 5 min. The cell pellets were then 
cultured in the tubes for 21 days in chondrogenic differentiation medium (40 μg/mL 
proline, 100 μg/mL sodium pyruvate, 10 ng/mL TGF-β3, 0.1 μM dexamethasone, 50 
μg/mL ascorbate 2 phosphate, 500 mg/mL BMP-6, and 1% ITS + premix in high glucose 
DMEM), with media replacement every 3-4 days. The MSCs formed a small spherical 
mass at the bottom of the tube and were then fixed with 4% paraformaldehyde, embedded 
in paraffin, and stained with Alcian Blue, which identifies glycosaminoglycans. 
 
4.2.4. Colony-forming unit fibroblast assay 
GNT-labeled MSCs were plated in 75 cm
2
 tissue culture flasks at 1×10
3
 
cells/flask in 12 mL αMEM. The cells were cultured for 7 days, with medium 
replacement every 3-4 days. Control flasks were plated with unlabeled MSCs. To 
enumerate CFU-F content, cultures were washed with 1×PBS, fixed with methanol, and 
stained with Giemsa stain. Colonies with 40 or more cells were counted under a 
stereomicroscope (2-5×). 
 
4.2.5. Population doubling time assay 
Unlabeled MSCs, Pluronic-treated MSCs, and GNT-labeled MSCs were prepared 
and separately replated on 96-well tissue culture plates at 1×10
3
 cells/well. At specific 
time points up to 144 h after seeding, cell proliferation was measured using a 
CyQUANT® Cell Proliferation Assay Kit (Molecular Probes, Inc.; Eugene, OR, USA) 
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during the cell growth long lag phase as described by Griffiths et al.
70
 In this kit, a green 
fluorescent dye, CyQUANT® GR dye, exhibits strong fluorescence enhancement when 
bound to cellular nucleic acids. Briefly, the medium was aspirated from the wells at 
specific time points and replaced with the CyQUANT® reagent. Fluorescence detection 
was measured on a microplate reader (TECAN Safire2
TM
) with filters appropriate for 
485/528 nm (excitation/emission). This assay is designed to produce a linear analytical 
response; therefore, a standard curve was generated by plating known numbers of MSCs 
on 96-well tissue culture plates and the fluorescence intensity values obtained from them 
after labeling with the CyQUANT® reagent were used to calculate cell numbers. 
 
4.2.6. Cell Adhesion 
Unlabeled, Pluronic-treated, and GNT-labeled MSCs were divided into two 
groups. The first group was processed with the acid-stripping protocol as described 
earlier in Section 3.2.3. The second group was prepared in the following manner: after 
incubation/labeling for 24 h, MSCs were washed three times with 1×PBS and lifted upon 
exposure to trypsin-EDTA for 5 min. The cell suspension was then passed through a 70 
µm nylon filter to eliminate large cell aggregates. 
Both groups were exposed to calcein AM (Invitrogen) for 30 min at 37 °C. The 
cells were then centrifuged for 3 min at 1500 rpm and resuspended in medium. Cells 
were plated at 2×10
5
 cells/well on a 96-well plate treated with various concentrations of 
either human plasma fibronectin (0-10 mg/mL) or pig collagen I (0-100 mg/mL) and 
blocked with 2% bovine serum albumin in tris-buffered saline (pH 7.5). After incubating 
for 30 min at 37 °C, the plate was then gently washed three times with 1×PBS (0.6 mM 
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MgCl2, 1.2 mM CaCl2) to remove unattached cells. A lysis buffer (50 mM Tris pH 7.5, 
1% NP-40, and 5 mM EDTA) was added to allow the fluorescent dye to be released from 
the cells. Fluorescence measurements were performed on a microplate reader (TECAN 
Safire2
TM
) with filters appropriate for 485/530 nm (excitation/emission). 
 
4.2.7. Transcriptome Analysis 
Total RNA samples of three sets of GNT-labeled MSCs and unlabeled MSCs 
from two different pig bone marrow donors were isolated using the Qiagen Micro 
RNeasy kit and QIAShredder homogenizer (Qiagen, Valencia, CA, USA) following the 
manufacturer’s protocol. The quantity of the extracted total RNA was measured by a 
Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Inc., Wilmington, DE, 
USA), and RNA integrity was assessed with an Agilent 2100 Bioanalyzer (Agilent, Palo 
Alto, CA, USA). Transcriptional profiles were assessed using GeneChip Porcine Genome 
Arrays (Affymetrix; Santa Clara, CA, USA) by the Genomic and RNA Profiling Core at 
Baylor College of Medicine (Houston, TX, USA). Signal intensities were evaluated by 
the in-house bioinformatician using the GeneChip Operating Software (Affymetrix). The 
data was preprocessed using the ITER normalization algorithm (Expression Console 
Software, Affymetrix). The differential expression analysis was performed using the 
Significant Analysis of microarrays (SAM) to identify the gene expressions that varied 
significantly between sample groups.
71
 The probe list obtained from the analysis was 
annotated using the annotation file provided by Tsai et al. 2006.
72
 This file identifies 
19675 of 24123 transcripts on the Affymetrix Porcine microarray, representing 11265 
unique genes, and provides conversion to the human gene accession IDs. The gene list 
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was uploaded to Metacore (GeneGo, Inc.), and pathway analyses were performed using 
the GeneGo Pathway Maps ontology. The False Discovery Rate (FDR) was 5%.  
 
4.2.8. Flow Cytometry of Cell Cycle Proteins 
Unlabeled MSCs, Pluronic-treated MSCs, and GNT-labeled MSC were prepared 
and suspended in fresh media at 1×10
6
 cells/mL. The cells were pelleted, washed once 
with 1×PBS, and the supernatant was discarded. To fix cells, the pellets were 
resuspended in 2 mL methanol and were allowed to sit overnight at -20 °C. The cells 
were then pelleted, washed once with 1×PBS, and suspended in 500 µL 0.25% Triton X 
in 1×PBS to permeabilize cellular membranes. The cells were kept on ice for 5 min and 
washed again with 1×PBS. Next, the cells were resuspended in 100 µL rinsing buffer 
(1% BSA in 1×PBS) containing 0.5 µg of the primary antibody (rabbit cyclin B1 (clone 
H-433; Santa Cruz Biotechnology, Inc.; Santa Cruz, CA, USA)) and were left in the dark 
for 1 h at 4 °C. The cells were then washed with rinsing buffer, resuspended in 100 µL 
rinsing buffer containing 0.5 µg of the secondary antibody (goat anti-rabbit IgG-FITC 
(ab6717, Abcam)), and incubated in the dark at RT for 30 min. The cells were washed in 
rinsing buffer, resuspended in the PI/RNase staining buffer (BD Pharmingen), and 
incubated in the dark for 20 min at RT. Flow cytometry was done on an LSRII Flow 
Cytometer (Becton Dickinson). FITC was excited with a 488 nm laser and FITC data 
were collected through a 530 ± 20 nm band pass filter. A 620 nm long pass filter was 
used to collected PI emission.  
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4.2.9. Quantitative Real-time Polymerase Chain Reaction 
Total RNA samples of three sets of GNT-labeled MSCs and unlabeled MSCs 
from three animals were isolated using the Qiagen Micro RNeasy kit and QIAShredder 
homogenizer (Qiagen, Valencia, CA, USA) following the manufacturer’s protocol. Total 
RNA was transcribed into cDNA using the RT² First Strand Kit (SABiosciences; 
Valencia, CA, USA) according to the manufacturer’s protocol. Expression levels of 
CKS2 and E2F1 were analyzed by quantitative real-time polymerase chain reaction (RT-
PCR) using oligonucletide primers designed from the Sus scrofa (pig) mRNA sequence 
database found on the NCBI website. The sequences of these oligonucleotides are 
detailed in Table 4.1. All reactions were performed in triplicate using the RT² SYBR® 
Green qPCR Mastermix (SABiosciences; Valencia, CA, USA) and following the 
manufacturer’s protocol on a 7900HT Fast Real-time PCR System (Applied Biosystems; 
Foster City, CA, USA). Hypoxanthine phosphoribosyltransferase (HPRT1) was chosen as 
the reference gene to normalize the amount of total RNA added to the reaction. Data are 
from at least three different experiments and are presented as relative intensities, 
normalized to HPRT1 cycle threshold (Ct) values. 
 
4.2.10. Statistical Analysis 
Unless otherwise noted, all experiments were conducted in triplicate. Results are 
presented as mean ± SEM. Statistical analysis between any two groups was performed 
using a two-tailed paired Student’s t test. Differences were considered statistically 
significant when p < 0.05. 
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Gene Forward Primer Reverse Primer 
Length 
(bp) 
CKS2 5’-TCAAACCGGGCTCGTTCGGC-3’ 5’-TGCAAGAGGGCGGGTAGCCT-3’ 139 
E2F1 5’-ATCAGCCCCGGGAAGACCCC-3’ 5’-CTGGGATCCGTGGCAGGGGA-3’ 125 
HPRT1 5’-CCGAGGATTTGGAAAAGGT-3’ 5’-CTATTTCTGTTCAGTGCTTTGATGT-3’ 183 
Table 4.1 – Forward and reverse primer sequences of genes analyzed in RT-PCR 
studies. bp = base pair. 
4.3. Results and Discussion 
4.3.1. Cell Characteristics after Labeling 
As multipotent progenitor cells, MSCs have the ability to differentiate into a 
variety of cell types. As seen in Figure 4.1, GNT-labeled cultures successfully 
differentiated into adipocytes, osteocytes, and chondrocytes. Upon appropriate induction, 
intracellular lipid vacuoles, alkaline phosphatase activity, and glycosaminoglycans were 
evidenced, respectively demonstrating adipo-, osteo-, and chondrogenic differentiation 
capacity of GNT-labeled MSCs. This establishes that the magnetic labeling of MSCs 
with GNTs did not affect the differentiation potential of the MSCs, which suggests that 
GNT-labeled MSCs may retain their therapeutic potential, which is critical for stem cell 
therapy. Quantitative analyses will be required to further corroborate the differentiation 
abilities of GNT-labeled MSCs. 
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Figure 4.1 – Histochemical stains of unlabeled and GNT-labeled MSCs exposed to 
(a) adipogenic, (b) osteogenic, or (c) chondrogenic media. In (a), the presence of 
intracellular lipid vacuoles is stained with Oil Red O; in (b), Vector red fluorescence 
marks the presence of alkaline phosphatase; in (c), Alcian blue stains the presence of 
glycosaminoglycans. Scale bar = (a) 50 µm, (b) 50 µm, and (c) 100 µm. 
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Figure 4.2 – Flow cytometry analysis performed on both unlabeled and GNT-
labeled MSCs to determine the expression of CD45, CD90, CD105, and CD29. 
Histograms represent (a) cells incubated with FITC-labeled mouse anti-pig CD45 
and PECy5-labeled mouse anti-human CD90, (b) cells incubated with the FITC-
labeled CD105, and (c) cells incubated with FITC-labeled mouse anti-pig CD29. 
Isotype control, red; MSC samples, green. 
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Another important cell characteristic is the cell surface marker expression on 
GNT-labeled MSCs. As such, flow cytometry was used to evaluate the expression of cell 
surface markers typically used to phenotype human MSCs (CD45, a marker for myeloid 
cells; CD90, a marker of primitive progenitor cells, and CD105, a truncated TGF-β 
receptor) upon the GNT-labeled pig MSCs. As seen in Figure 4.2, MSCs are CD45
-
CD90
+
, as expected; however, a small fraction of pig MSCs were CD105
+
, which differs 
from human MSCs. Labeled cells displayed similar rates of expression for CD45
-
CD90
+
 
(GNT-labeled MSCs: 94.40%; unlabeled MSCs: 94.13%) and also for CD105 (GNT-
labeled MSC: 10.80%; unlabeled MSCs: 12.62%) to their unlabeled counterparts. CD29
+
 
(β1 integrin), a ubiquitous cell marker, was expressed by the majority of both unlabeled 
(97.57%) and GNT-labeled MSCs (96.29%). According to these findings, GNT labeling 
does not affect the expression of cell surface markers, but a more comprehensive analysis 
of gene and protein expression is necessary to validate GNTs as innocuous agents for cell 
labeling. Currently, the effect of GNT labeling on gene expression is being investigated 
in our laboratories by microarray analysis. 
 
4.3.2. Growth Kinetics 
To evaluate the self-renewal properties and proliferation capacity of GNT-labeled 
MSCs, colony-forming unit fibroblast (CFU-F) and population doubling time (PDT) 
assays were performed. As seen in Table 4.2, both studies suggest that GNTs do not 
impair either the self-renewal or the proliferation kinetics of MSCs. In fact, the GNT 
labeling and Pluronic treatment increased the self-renewal rate of MSCs by 
approximately 27% and 19%, respectively, after 7 days.  
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Cells PDT (h) Plating Density (cells/well) CFU-F after 7 days 
Unlabeled 25.5 1000 252 ± 11 
Pluronic-treated 21.0 1000 301 ± 7 
GNT-labeled 22.1* 1000 319 ± 9* 
Table 4.2 – Population doubling time (PDT) and colony-forming unit fibroblast 
(CFU-F) results of unlabeled MSCs, Pluronic-treated MSCs, and GNT-labeled 
MSCs. *Statistical differences (P < 0.05) were observed for both PDT and CFU-F 
comparisons when compared to unlabeled MSCs. 
Since an extended lag phase was observed earlier in the pulse-chase experiment 
(Section 3.3.2), growth curves of cells derived from three additional animals were 
generated to depict and confirm the extended lag phase experienced by the GNT-labeled 
MSCs. As seen in Figure 4.3, both Pluronic-treated MSCs and GNT-labeled MSCs 
exhibited an extended lag phase lasting 48 h and 72 h, respectively. Interestingly, after 
starting the growth log phase, both the Pluronic- and GNT-labeled MSCs were able to 
reach similar cell numbers as unlabeled MSCs by 144 h, suggesting that their rate of cell 
division was equivalent to the control after the initial growth delay, which is in agreement 
with the calculated PDT and CFU-F values in Table 4.1.  
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Figure 4.3 – Growth kinetics of unlabeled MSCs, Pluronic-treated MSCs, and GNT-
labeled MSCs over 144 h after cell labeling. * indicates  p < 0.05 when compared to 
Unlabeled MSCs, and 
§
 indicates p < 0.05 when compared to Pluronic-treated 
MSCs. 
4.3.3. Cell Adhesion 
The effects of GNT labeling on MSC adhesion properties were studied. A cell 
adhesion assay was used to evaluate the interaction of unlabeled, Pluronic-treated, and 
GNT-labeled MSCs with collagen I and fibronectin, which are two major components of 
the extracellular matrix (ECM). Besides serving as structural support for cell adhesion, 
fibronectin and collagen I are involved in vital cell signaling pathways through their 
interactions with cell adhesion receptors, such as integrins.
73,74
 Ideally, a dose-response 
curve is observed when measuring the intensity of fluorescently-labeled MSCs that 
successfully bind to culture plates treated with increasing ECM protein concentration. 
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Although it has been previously established that the class of Pluronic surfactants can be 
used as excellent anti-adhesives for cell cultures,
75
 Figure 4.4a and b suggests that 
Pluronic F-108 does not hinder cell adhesion to ECM proteins as significantly as GNTs 
do. MSCs incubated with Pluronic F-108 behaved similarly to unlabeled MSCs, while 
GNT-labeled MSCs showed a decreased response to both fibronectin and collagen I. This 
observation that Pluronic F-108 does not inhibit cell adhesion while in the presence of 
ECM proteins has similarly been evidenced with neuroblastoma cells.
76
 Additional 
studies are currently underway in our laboratories to determine whether the GNTs are 
physically blocking cell adhesion receptor sites or chemically altering the cell adhesion 
properties of the labeled MSCs. 
However, it was determined that the acid-stripping protocol used to clean the 
GNT-labeled MSCs deterred cell adhesion to collagen I (Figure 4.4d). The unlabeled, 
Pluronic-treated, and GNT-labeled MSCs all lost their ability to adhere to collagen I 
when treated with the acid strip buffer solution, while those not treated with the acid-strip 
buffer solution retained their cell adhesion properties. Additionally, the acid-stripping 
protocol did not affect the cell adhesion response to fibronectin (Figure 4.4c). This 
suggests that the acid-stripping protocol may be modifying the integrins involved in 
collagen I adhesion and not those involved in fibronectin adhesion. While the loss of 
collagen I adhesion may be disadvantageous in some respects, our studies have 
demonstrated that the acid-stripped GNT-labeled MSCs do not lose their important stem 
cell characteristics. 
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Figure 4.4 – Cell adhesion properties of unlabeled, Pluronic-treated, and GNT-
labeled MSCs. Non-acid-stripped MSC response to (a) fibronectin and (b) collagen 
I. (d) Acid-stripped MSC response to (c) fibronectin and (d) collagen I. Note: error 
bars may be smaller than the symbols; * represents statistical difference (P < 0.05). 
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4.3.1. Transcriptome Analysis 
Transcriptome analysis was performed on samples of concurrently prepared 
unlabeled MSCs and GNT-labeled MSCs derived from two different animals. Appendix 
B contains the heat maps corresponding to the 123 genes that were differentially 
expressed in GNT-labeled MSCs, with 64 genes that were significantly upregulated and 
59 downregulated. The differences for both up- and down-regulated gene expression 
levels were relatively moderate (-5.1 to 5.6), which largely mirrors the observations from 
the functional evaluation of GNT-labeled MSCs previously described, i.e. a non-
apoptotic transient cell cycle arrest (Figure 4.3 and Figure A2 from Appendix A) and 
some degree of disturbance in cell adhesion properties (Figure 4.4). A survey of the 
affected genes and their related pathways suggested that GNT labeling led to changes in 
cellular inflammatory/stress response, oxidative stress response, and the cell cycle 
(Appendix C). 
The cellular stress response is a defense reaction of cells towards damage inflicted 
by environmental forces on macromolecules (DNA or proteins). The cellular stress 
response involves physiological mechanisms of sensing membrane lipid, protein, and 
DNA damage,
77
 redox sensing and regulation, cell cycle control, macromolecular 
stabilization/repair, and control of energy metabolism. If tolerance levels of stress are 
surpassed, cells are able to activate programmed death (apoptosis). Among the 
upregulated transcripts detected in GNT-labeled MSCs, several members belong to the 
minimal stress proteome,
77
 which are a group of stress proteins found to be conserved in 
all three living organism kingdoms. These conserved proteins include Superoxide 
Dismutase (SOD2; +3.9-4.1) and Aldo-keto Reductase (AKR1C4/L1; +3.8). Transcripts 
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for inflammatory cytokines such as Interleukin-6 (IL6; +4.7) and Leukemia Inhibitory 
Factor (LIF; +3.9) were also upregulated. 
 
Figure 4.5 – A depiction of the cell cycle and the relevant genes downregulated after 
the incorporation of GNTs into MSCs. 
Transcriptional patterns of apoptosis-associated genes were limited to a few 
transcripts, such as BIRC5 (also known as Survivin; -3.1) and BNIP3 (+3.1). Another 
evidence of the stress response by GNT-labeled MSCs comes from the upregulation the 
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha 
(NFKBIA; +3.5), which inhibits NF-κB transcription factors from binding to DNA to 
induce transcription and keeps them sequestered in an inactive state in the cytoplasm.  
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The transcriptome data analysis clearly corroborates the observations seen in the 
growth kinetics study in which a transient cell cycle arrest was detected. As shown in 
Figure 4.5, GNT-labeled MSCs showed a downregulation of 24 transcripts for cell cycle 
regulators encompassing G1/S transition (E2F1 (-4.2) and CDCA3 (-4.1)), DNA 
replication (GINS1 (-4.0), CDC45 (-2.8), CHAF1 (-3.7), PCNA (-5.1), FEN-1 (-3.2), 
MCM-2 (-3.1), and MCM-4 (-3.3)), and termination of the mitotic phase (CKS2 (-3.8), 
Cyclin B1 (-3.7), Cyclin B2 (-3.1), Condensin (also known as NCAPG; -3.5), SKA 1 (-
3.1), SKA 2 (-2.9 to -3.2), Fbox-5 (-4.1), INCENP (-2.9), CCDC99 (-4.3), MIS18 (-3.4), 
Survivin (-3.1), RCS1 (also known as FAM64; -3.3), KIF23 (-3.4), PLK4 (-3.2), and 
PRC1 (-3.3)).  In addition, significant changes in cell cycle inhibitors were observed, 
such as the downregulation of TCF19 (-3.9) and the upregulation of Cyclin G2 (+3.4). A 
description of the 24 transcripts is detailed in Appendix D. 
To validate the findings of GNT effects on cell cycle, additional studies were 
performed using RT-PCR (Figure 4.6) to confirm transcript abundance for CKS2, a 
protein that binds to the catalytic domain of cyclin-dependent protein kinases and 
constitutes an essential component for their activity in cell cycle regulation, and E2F1, an 
essential transcription activator of proteins involved in DNA replication and cell cycle 
progression from the G1 to S phase. The validation studies were performed with MSCs 
isolated from animals different (validation samples) from those used for the microarray 
analysis. The downregulation of CKS2 by GNT-labeled MSCs was confirmed only in 
samples after overnight exposure to GNTs (Figure 4.6a). No differences were found at 24 
and 48 h post-labeling. CKS2 in GNT-labeled MSCs increased with time, indicating that 
cell cycle mechanisms had been restored.  Similarly, E2F1 expression was downregulated 
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after overnight exposure to GNTs and gradually increased over time (Figure 4.6b). 
Although statistical significance was not observed due to the small sample size, the data 
is encouraging but will nevertheless require additional samples. 
 
Figure 4.6 – Quantitative Real-time PCR data depicting the relative expression 
levels of (a) CKS2 and (b) E2F1 over 48 h by unlabeled MSCs, Pluronic-treated 
MSCs, and GNT-labeled MSCs. All results were normalized to the Ct values of the 
HPRT1 reference gene. 
Cell cycle in GNT-labeled MSCs of the validation samples was further analyzed 
by flow cytometry using an anti-pig Cyclin B1 FITC-labeled antibody and propidium 
iodide (PI) staining to determine cell cycle phases by DNA content. Complete flow 
cytometry figures are provided in Appendix E. Figure 4.7 displays the distribution of 
cells throughout the distinct cell cycle phases. Figure 4.7b showed a decreased amount of 
cells in the S phase for GNT-labeled MSCs and Pluronic-treated MSCs, in comparison to 
unlabeled MSCs, indicating that these cells were less engaged in proliferation than the 
controls. Cell cycle arrest can be defined by an accumulation of cells in G2/M phase and 
lower expression of Cyclin B1. As anticipated, an increased amount of GNT-labeled 
(b)(a)
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MSCs in the G2/M population after 24 h (Figure 4.7c) and a significant decrease in 
Cyclin B1 expression (Figure 4.7d) were observed, which was extended up to 48 h after 
labeling. With these findings corroborating the previously described results of the 
functional evaluations, the transcriptome analysis supported the fundamental conclusions 
that the incorporation of GNTs by MSCs leads to a transient, non-apoptotic cell cycle 
arrest. 
 
Figure 4.7 – Flow cytometry data depicting the cell population (n = 10,000) 
distribution in the (a) G0/G1, (b) S, and (c) G2/M phases of the cell cycle and (d) 
Cyclin B1 expression levels for unlabeled MSCs, Pluronic-treated MSCs, and GNT-
labeled MSCs. * indicates statistical significance (p < 0.05). 
(a)
(c) (d)
* **
*
(b)(a)
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Chapter 5 
Gadonanotubes as Magnetic Facilitators for 
Enhancing Stem Cell Retention 
5.1. Introduction 
In addition to the inability to noninvasively track cells within the body in real-
time, the low rate of retention and survival of transplanted cells remains a challenge in 
the development of stem cell therapy, irrespective of the cell type, model, and injection 
method used.
78
 When delivering cells to the heart, the high loss of transplanted cells is 
attributed to the mechanical obstacles presented at the sites of injection, particularly 
cardiac contraction and blood flow.
79
 Because the success of stem cell therapy is strongly 
dependent on the successful delivery, survival, and integration of the cells, researchers 
have recently been developing strategies to improve cell retention and viability upon 
transplantation. One current approach is to target biomolecules such as antibodies, 
adhesion molecules, and other proteins in order to augment cell adhesion and 
engraftment.
78
 Physical methods have also been developed, such as transplanting cells 
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embedded into hydrogels
80
 or as 3D constructs,
18
 to help cells withstand the mechanical 
challenges in the heart. Additionally, magnetic targeting of superparamagnetic iron-
labeled cells has been used to induce cell homing to grafts, stents, and cardiac tissue. This 
particular approach has proven to be safe and easily translatable to the clinical setting, in 
addition to being effective in improving both short- and long-term cell retention in the 
heart.
23,34,81
 
Along with being developed as a T1-weighted intracellular MRI CA, GNTs are 
presently being used to magnetically improve the retention of transplanted MSCs during 
cardiac injections. When internalized by MSCs, the superparamagnetic GNTs render the 
cells magnetically active, thus allowing for GNT-labeled MSCs to be magnetically 
attracted to an external magnetic field. This chapter describes the in vitro, ex vivo, and in 
vivo experiments that exploits this phenomenon to develop a new therapeutic application 
of GNTs as a magnetic facilitator to increase the retention of transplanted stem cells. 
 
5.2. Materials and Methods 
5.2.1. Cell Culture and Labeling 
MSCs were harvested and isolated from the bone marrow of male pigs as 
described elsewhere.
53
 MSCs were expanded in two successive passages at 2×10
3
 
cells/cm2. Cells in the second passage (P2) were then frozen in cryovials, and at 
appropriate times, MSCs were thawed and expanded once (P3) prior to labeling. Cell 
cultures were incubated at 37 °C (95% relative humidity in 5% CO2). Unless otherwise 
specified, MSCs were grown and maintained in alpha minimal essential medium 
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(αMEM) containing 10% fetal bovine serum (FBS) and 1% antibiotic supplement (200 
mM L-glutamine, 10,000 units/mL penicillin, and 10 mg/mL streptomycin). All labeling 
studies were performed with P3 MSCs. 
Four cell populations were cultured and used in the subsequent studies: (1) GNT-
labeled MSCs, (2) MSCs labeled with ultrasmall superparamagnetic iron oxide 
nanoparticles (USPIO-labeled MSCs), (3) MSCs labeled with 20 nm colloidal 
diamagnetic lutetium (Lu-labeled MSCs), and (4) unlabeled MSCs. GNT-labeled MSCs 
were prepared by incubating MSCs with GNTs (27 µM Gd
3+
) for 24 h on 175 cm
2
 cell 
culture flasks and processed as earlier described in Section 3.2.3. For preparing USPIO-
labeled MSCs, 125 µL of USPIO nanoparticles (Molday ION(-); 10 mg Fe/mL; 
Biophysics Assay Laboratory, Inc.; Worcester, MA, USA) was diluted with 400 µL cell 
culture grade water. To this solution, 12.5 µL PLL (10 mg/mL; Biophysics Assay 
Laboratory, Inc.; Worcester, MA, USA) was added. The USPIO-PLL conjugate solution 
was gently vortexed, incubated at 25 °C for 20 min, and stored at 4 °C. Prior to cell 
labeling, the solution was revortexed, incubated at 25 °C for 20 min, diluted in 12 mL 
αMEM, and thoroughly mixed. The SPIO-PLL solution was added to 12.5 mL αMEM 
into each 175 cm
2
 cell culture flask to yield a final concentration of 50 µg Fe/mL and 5 
µg/mL PLL. After 24 h incubation, the USPIO-labeled MSCs were washed three times 
with 1×PBS and passed through a 70 µm nylon filter to remove large cell aggregates. To 
prepare Lu-labeled MSCs, MSCs were incubated in 2 v/v% colloidal lutetium (BioPAL 
CellTrack
TM
; Biophysics Assay Laboratory, Inc.; Worcester, MA, USA) in αMEM for 24 
h, washed three times with 1×PBS, and passed through a 70 µm nylon filter. 
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5.2.2. Magnetic Cell Adhesion 
GNT-labeled MSCs, USPIO-labeled MSCs, and unlabeled MSCs were separately 
prepared, collected, and suspended at 5×10
5
 cells/mL in running buffer (10 mM Tris, 103 
mM NaCl, 24 mM NaHCO3, 5.5 mM glucose, 5.4 mM KCl and 2 mg/ml BSA, pH 7.4). 
Cells were then tested using a parallel plate flow-fluid shear stress rolling assay, which 
was modified from a previous procedure.
82
 Briefly, 24×50 mm slides were cut from 
15×100 mm polystyrene Petri dishes. The slides were then washed with 1×PBS, blocked 
with 2% BSA for 2 h at 25 °C and assembled to a parallel plate flow chamber. To assess 
the magnetic adhesion of MSCs, a 1.3 T ring NdFeB magnet (RX4C2, K&J Magnetics; 
Jamison, PA, USA) was attached to the slide. The cells were then injected into the flow 
chamber and running buffer was drawn through the chamber at a constant force of 1 
dyne/cm
2
 for 5 min using a computer-controlled syringe pump (Harvard Apparatus; 
Holliston, MA, USA). The number of adherent cells remaining was recorded by digital 
microscopy (VI-470 charge-coupled device (CCD) video camera; Optronics Engineering) 
at 20× on an inverted Nikon DIAPHOT-TMD microscope. The buffer solution that was 
passed through the chamber was collected and centrifuged to recover cells that were not 
magnetically retained in the chamber. The recovered cells were fixed with 2% 
paraformaldehyde in 1×PBS and analyzed by flow cytometry (FACS Calibur BD). A gate 
using forward and side scatter to distinguish live cells (from debris) was employed. The 
number of gated events was used to quantify recovered cells (% of cells not retained in 
the chamber by the magnet), which in turn was used to determine the amount of 
magnetically adherent cells (% of cells retained in the chamber by the magnet). 
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5.2.3. Ex Vivo Perfusion 
An excised bovine heart received three separate 0.2 mL transepicardial bolus cell 
injections (100×10
6
 cells/mL in 2% FBS) approximately 5 mm into the left ventricle 
(Figure 5.1): (1) GNT-labeled MSCs with a 1.3 T cylindrical NdFeB magnet (D66SH; 
K&J Magnetics; Jamison, PA, USA) held in place over the injection site using surgical 
tape, (2) GNT-labeled MSCs without a magnet, and (3) unlabeled MSCs. The injection 
sites were demarcated with sutures. The heart was perfused with cold saline solution for 
72 h, kept in 10% formalin for 24 h, and prepared for histopathological analysis. A 1.7 
cm slice, perpendicular to the long axis of the heart, was taken, approximately 6 mm 
above and 6 mm below the suture marks. The portion of wall containing each injection 
site was removed from the slice and subsequently sectioned into 5 levels. Adjacent tissue 
sections were stained with hematoxylin and eosin. 
 
Figure 5.1 –Photographs depicting the ex vivo perfusion of an excised bovine heart. 
(a) Prior to perfusion, GNT-labeled MSCs were injected into the left ventricle at 
Sites 1 and 2, while unlabeled cells were injected at Site 3. At Site 1, a 1.3 T 
cylindrical NdFeB magnet was held in place by surgical tape over the injection site. 
(b) After injection, the heart was perfused with cold saline solution for 72 h. 
(a) (b)
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5.2.4. In Vivo Retention 
GNT-labeled MSCs and Lu-labeled MSCs were prepared, collected, separately 
suspended in 2% FBS, and kept on ice in sterile polystyrene tubes until injection. Three 
aliquots (0.2-2×10
6
) of each cell population were also collected in glass scintillation vials 
for elemental analysis. All animal care was in accordance to the Institutional Animal Care 
and Use Committee (IACUC) guidelines of the Texas Heart Institute. Left thoracotomy 
was performed on female juvenile pigs (n = 12 total) under general anesthesia. A 
sterilized 1.3 T NdFeB ring magnet (RX4C2; K&J Magnetics; Jamison, PA, USA) was 
sutured with prolene stitches onto the anterior wall of the left ventricle (Figure 5.2). Cells 
were gently pipetted prior to the transepicardial injections, which were completed with a 
21-gauge butterfly needle around the inner and outer perimeters of the ring magnet. The 
pigs were divided into the following four groups: 
 In Group A (n = 3), 12×106 Lu-labeled MSCs were administered in three 0.1 mL 
injections, followed by 12×10
6 
GNT-labeled MSCs in a similar manner. After 
being maintained in the operating room for 1 h, the animals were euthanized. The 
left ventricle (LV) encompassing the injection site, the right ventricle (RV), and the 
paratracheal/periaortic lymph nodes (LN) were collected for analysis. 
 In Group B (n = 3), 12×106 Lu-labeled MSCs were administered in three 0.1 mL 
injections, followed by 12×10
6 
GNT-labeled MSCs in a similar manner. The 
thoracic incisions were closed and the animals were monitored during recovery. 
After 48 h, the animals were euthanized. The LV encompassing the injection site, 
the RV, and the LN were collected for analysis. 
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 In Group C (n = 3), 9.6×106 Lu-labeled MSCs were administered in six 0.2 mL 
injections, followed by 9.6×10
6
 GNT-labeled MSCs in a similar manner. After 
being maintained in the operating room for 0.5 h, the thoracic incisions were closed 
and the animals were monitored during recovery. At 24 h after the time of 
injection, the animals were euthanized. The LV encompassing the injection site, the 
RV, and the LN were collected for analysis. 
 In Group D (n = 3), 9.6×106 Lu-labeled MSCs were administered in six 0.2 mL 
injections, followed by 9.6×10
6
 GNT-labeled MSCs in a similar manner. After 
being maintained in the operating room for 1 h, the thoracic incisions were closed 
and the animals were monitored during recovery. At 24 h after the time of 
injection, the animals were euthanized. The left LV encompassing the injection 
site, the RV, and the LN were collected for analysis. 
 
Figure 5.2 – Photograph depicting a typical in vivo MSC injection procedure around 
a 1.3 T NdFeB ring magnet sutured to the left ventricle of the porcine model. 
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5.2.5. Sample Digestion and Elemental Analysis 
All tissue samples were frozen for 24 h and lyophilized for 48 h to remove all 
water content. In Erlenmeyer flasks with borosilicate glass beads, diced tissue samples 
were slowly added to 70% trace-metal grade HNO3 at 110 °C until all tissues were 
completely dissolved. After having dried for 12 h at 220 °C, samples were treated twice 
with alternating additions of 25% HClO3 and 70% HNO3 at 110 °C, allowing for samples 
to dry in between each acid addition. Samples were allowed to cool, diluted to 30 mL 
with 2% trace-metal grade HNO3, and filtered through a 0.22 µm syringe filter. 
Cell samples were heated with 500 µL 25% HClO3 until boiling. Once the 
samples turned from yellow to colorless, an additional aliquot of HClO3 was added and 
heated to evaporation. The samples were then diluted to 10 mL with 2% trace-metal 
grade HNO3 and filtered through a .22 µm syringe filter. 
Inductively-coupled plasma-mass spectrometry (ICP-MS) analyses were 
performed by a PerkinElmer Elan 9000 Inductively-Coupled Plasma-Mass Spectrometer. 
From the concentration of gadolinium or lutetium ions and the total cell number in each 
sample, the average metal ion uptake by each cell was calculated and was applied to 
calculating the amount of cells retained in tissue samples. The measurements were 
performed in triplicate and the mean and standard deviations of the results were 
calculated. 
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5.2.6. Statistical Analysis 
Unless otherwise noted, all experiments were conducted in triplicate. Results are 
presented as mean ± SEM. Statistical analysis between any two groups in the in vitro 
rolling assay was performed using a two-tailed unpaired Student’s t test. Statistical 
analysis between any two groups in the in vivo retention studies was performed using a 
one-tailed paired Student’s t test. Differences were considered statistically significant 
when p < 0.05. 
 
5.3. Results and Discussion 
5.3.1. Cell Adhesion 
To assess whether cellular magnetic labels, such as GNTs and USPIOs, render 
MSCs magnetically active, a modified parallel-plate fluid flow chamber rolling assay was 
performed. Conventionally, this assay is used to evaluate cell adhesion to and movement 
over various proteins and other small molecules that have been immobilized on a glass 
slide, over which a fluid sheer stress is applied to mimic the dynamic fluid flow in 
physiological environments.
82
 Rather than studying chemical adhesion, this present study 
observed the magnetic adhesion of GNT-labeled MSCs, USPIO-labeled MSCs, and 
unlabeled MSCs to a 1.3 T NdFeB ring magnet attached to the glass slide. After having 
been challenged with a constant fluid shear force of 1 dyne/cm
2
 for 5 min, approximately 
56.9% of GNT-labeled MSCs were magnetically retained on the slide; in comparison, 
90.7% of USPIO-labeled MSCs were magnetically adherent (Figure 5.3). While not as 
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magnetically active as USPIO-labeled MSCs, GNT-labeled MSCs demonstrated a 
significant attraction to an external magnetic field, even when challenged under similar 
mechanical stress normally experienced by vascular smooth muscle cells.
83
 
 
Figure 5.3 – Magnetic retention of unlabeled MSCs, GNT-labeled MSCs, and 
USPIO-labeled MSCs in a modified parallel-plate fluid flow chamber rolling assay. 
 
5.3.2. Ex Vivo Perfusion 
Upon discovering that GNT-labeled MSCs are attracted to a nearby external 
magnetic field, ex vivo perfusion studies using bovine hearts were completed to 
demonstrate that the proximity of an external magnet improves the retention of GNT-
labeled MSCs injected into cardiac muscle. After 72 h perfusion, drainage of the dark 
GNT-labeled MSCs was observed in the epicardial vein above Site 2 (Figure 5.4a).  
Pathological analysis of the bovine heart suggests that the external magnet assists 
in concentrating the injected GNT-labeled MSCs at the target site, as opposed to both 
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unlabeled MSCs and GNT-labeled MSCs without a magnet, which disseminate 
throughout the tissue and vasculature (Figure 5.4b and c). The tissue slice containing Site 
1 showed an area of GNT-labeled MSCs 4-5 mm in diameter located approximately 5 
mm from the epicardial surface. Microscopic analysis showed concentrated clusters of 
GNT-labeled MSCs at interstitial spaces, with little signs of additional dissemination. At 
Site 2, a smaller area of GNT-labeled MSCs approximately 3 mm in diameter consisting 
of several small black clusters was found less than 2 mm from the epicardial surface. In 
addition, the subendocardial region showed areas of grayish discoloration, suggestive of 
the presence of disseminated GNT-labeled MSCs. The GNT-labeled MSCs were found in 
interstitial spaces in smaller clusters than those at Site 1, as well as in the lumen of 
various epicardial capillaries and veins. Similarly for Site 3, small clusters of unlabeled 
MSCs were found approximately 2 mm from the epicardial surface. Dissemination of the 
MSCs was also apparent throughout various nearby venous cavities.  
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Figure 5.4 – (a) Photograph of the perfused heart after formalin fixation. Arrows 
denote venous drainage of GNT-labeled MSCs was seen above Site 2. (b) H&E 
staining of Injection Sites 1, 2, and 3. Magnification: 4×. (c) Various levels of the 
tissue segments containing Injection Sites 1 and 2.  Arrows denote an area of grayish 
discoloration, suggestive of disseminated GNT-labeled MSCs. 
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5.3.3. In Vivo Retention 
To simultaneously assess the retention efficiency of magnetically-facilitated cell 
injections and the biocompatibility of a sutured strong magnet to the left ventricular 
epicardium, four in vivo porcine model groups were studied, each with varied times of 
magnet exposure and times of sacrifice. In addition to being a well-established model in 
safety and efficacy for cardiovascular studies, swine is preferred over smaller animal 
models (such as mice and rats) for its similarities to human cardiovascular anatomy, 
physiology, and remodeling kinetics. Groups A and B evaluated the short-term (1 h) and 
long-term (48 h) tolerance of the magnet, while Groups C and D examined the optimal 
amount of time needed (0.5 or 1 h, respectively) for the magnet to be applied to the heart 
before the pigs were sacrificed at 24 h after cell injection. To serve as a control, a 
population of MSCs was labeled with diamagnetic colloidal lutetium, which can be 
quantifiable upon elemental analysis. 
All treated pigs remained viable and showed no signs of physiological or 
behavioral trouble for the duration of the experiment. However, an inflammatory 
response was apparent around the magnet after having been sutured to the heart for 48 h 
in Group B (Figure 5.5). Test groups evaluating longer-term in vivo magnet exposure for 
7 days and 30 days are currently underway. 
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Figure 5.5 – Photograph depicting the heart’s inflammatory response to the sutured 
magnet after 48 h in a pig of Group B. Courtesy of Luiz Sampaio, M.D. 
In vivo injection studies corroborated the ex vivo perfusion study results, 
demonstrating that magnetic facilitation can improve transplanted MSC retention at target 
injection sites in the heart. As seen in Figure 5.6, the retention efficiency of GNT-labeled 
MSCs is approximately twice as that of Lu-labeled MSCs. While one out of every three 
pigs in each group retained equivalent amounts of GNT-labeled MSCs and Lu-labeled 
MSCs at the injection site (Figure 5.6 insets), the majority of the pigs retained between 
1.5 to 3.3 times more of GNT-labeled MSCs than the diamagnetic Lu-labeled MSC 
control, irrespective of magnet exposure or sacrifice times. This is similar to the retention 
rates exhibited by magnetically targeted iron-labeled cardiosphere-derived cells injected 
into mouse hearts after 24 h.
23
 Interestingly, a significant amount of GNT-labeled MSCs 
were detected in the right ventricle and the paratracheal/periaortic lymph nodes, with 
retention numbers increasing with longer sacrifice times; however, negligible amounts of 
Lu-labeled MSCs were detectable in the these control tissue samples, suggesting the 
majority of these cells are primarily lost by vasculature flow. 
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Figure 5.6 – Retention efficiencies of GNT-labeled MSCs (Gd) and Lu-labeled MSCs 
(Lu) in the left ventricle (LV), right ventricle (RV), and paratracheal/periaortic 
lymph nodes (LN) of each in vivo porcine model of (a) Group A, (b) Group B, (c) 
Group C, and (d) Group D. Insets illustrate the histographic distribution of each pig 
sample (n = 3). * indicates  p < 0.05 when compared to Lu, and 
§
 indicates p < 0.1 
when compared to Lu. 
Because there is no clear advantage to longer magnet application times (48 h) 
over shorter times in terms of retention efficiencies, future studies should have short 
magnet application times for surgical simplicity. Similarly, cell retention rates are similar 
between Groups C and D (Figure 5.6c and d, respectively), suggesting more experiments 
are warranted to determine the optimal magnet application time.    
(a) (b)
(c) (d)
*
* *
*
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The presented in vivo study has several limitations that must be addressed in 
future studies. First, the current method of transepicardial injections may not be the most 
practical and optimal means of cell transplantation. During many of the experiments, cell 
injection solutions leaked from the tissue injection sites immediately after syringe needle 
extraction due to the backpressure of the tissue, resulting in a significant source of cell 
loss. Additionally, dark gray residue, suggestive of GNT-labeled MSCs, was found on the 
surface of the sutured magnet after tissue extraction in Group B. This observation implies 
that the magnet may be extracting GNT-labeled cells through the channels created by the 
syringe needle over time, which presents another source of cell loss. A possible solution 
to this issue is to endocardially deliver cells around an epicardially-sutured magnet, 
which would allow for cardiac muscle to physically separate the magnet from the cells 
and needle channels created. Additionally, the inability to avoid injecting cells directly 
into cardiac veins and other types of vasculature presents an inherent source of cell loss. 
While the present results are promising, the number of test subjects in each group must be 
increased to provide more statistically-relevant results.  
Second, different experimental variables must be optimized to determine the most 
effective method of cell transplantation and magnetic retention. The optimal cell type, 
cell dose, timing of delivery, location of delivery, and delivery technique all currently 
remain unknown to researchers studying cardiac cell therapy.
84
  These factors must first 
be determined in order to better realize the benefit of magnetically facilitating cell 
retention with an external magnetic source. Also, the most effective magnet type, 
strength, and placement method must be established. 
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Lastly, more effort is needed to improve the clinical feasibility and translatability 
of the current method. Conventionally, transendocardial and intracoronary injections are 
preferred for stem cell therapy, with the intention of keeping procedures as noninvasive 
as possible.
85
 As such, a new method must be developed to introduce a strong magnet 
field source proximal to the injection sites in a minimally invasive manner. The magnetic 
source must also be biocompatible and clinically practical (i.e. not interfering with 
surgical procedures and medical equipment). Additionally, ischemic models should also 
be used in future studies to better mimic the physiological conditions found in patients’ 
hearts and to better assess the effectiveness of magnetic cell retention.  
Although the present study is nascent and requires further improvement, the 
current results have clearly demonstrated that GNTs are effective magnetic facilitators. In 
addition to being preclinically safe, the proposed method of cell transplantation has 
proven to be effective in increasing GNT-labeled MSC retention in the presence of an 
external magnetic field when compared to control cells. As possibly the first T1-weighted 
MRI intracellular theranostic agent, it is expected that the GNTs may greatly improve the 
efficacy of current cell therapies for the treatment of cardiac disease. 
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Chapter 6 
Conclusions and Future Work 
6.1. Conclusions 
With over 2,000 stem cell-based clinical trials currently underway, the need for 
better in vivo cell tracking technologies is apparent. With such technologies in place, the 
development of stem cell-based therapeutics for the prevention, detection, and treatment 
of human diseases should progress more rapidly, since cell tracking helps elucidate stem 
cell migration and tissue integration, determine the effective dose of delivered stem cells 
to a target organ, and monitor cell-based therapeutic delivery.  
This work describes the successful intracellular labeling of MSCs with GNTs, as 
confirmed by TEM imaging and elemental analysis. It is also seen that GNTs are not 
released from the cells for up to 72 hours after incorporation. The GNT-labeled MSCs 
produce a brighter T1-weighted MR phantom image and exhibited a nearly two-fold 
decrease in T1 relaxation when compared to unlabeled MSCs, implying that the GNTs 
 81 
 
represent a new, high-performance biotechnology for stem cell labeling and possibly in 
vivo cell tracking by real-time MRI. With the possibility of becoming the first T1-
weighted MRI intracellular imaging agent, the GNTs could become a new paradigm for 
the in vivo labeling of any mammalian cell.  
Before translating this technology into the clinic, the short- and long-term cellular 
response to the intracellular incorporation of GNTs needs to be assessed. As profiled by 
various in vitro assays, GNTs can successfully be internalized by MSCs without affecting 
cell viability, differentiation potential, or phenotypic characteristics. However, GNT-
labeled MSCs show decreased adhesion to collagen and fibronectin and demonstrate an 
extended growth lag phase (48 h) when compared to unlabeled MSCs (24 h). A 
comprehensive transcriptome analysis indicates that more than 130 genes were 
significantly altered, including those involved in cell cycle, DNA damage, and stress 
response pathways. Supporting data confirm that a non-proliferative, non-apoptotic 
growth arrest is effectively occurring in GNT-labeled MSCs. Nonetheless, these events 
are found to be transient, as GNT-labeled MSCs exhibit the same adhesion properties and 
growth kinetics profile as unlabeled MSCs shortly after this lag phase. 
Along with being developed as an intracellular MRI agent, the magnetically-
active GNTs can be used as a magnetic facilitator to improve the retention of GNT-
labeled MSCs in cardiac tissue during cardiomyoplasty.  Because transplanted cell 
retention is low by any current method of delivery,
14
 innovative and translatable 
strategies to improve cell homing and survival, which translate into better therapeutic 
outcomes of cardiomyoplasty, are highly desirable. Upon discovering that GNT-labeled 
MSCs are attracted to an external magnetic source, results from in vitro rolling assays 
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and ex vivo perfusion studies further corroborate that the proximity of an external magnet 
concentrates GNT-labeled MSCs at targeted sites of injection, even after being 
challenged by fluid shear force perfusion mechanics. The completed in vivo porcine 
injection studies clearly demonstrate that the GNTs are effective magnetic facilitators in 
improving the retention of transplanted cells by up to three times more than unlabeled 
MSCs in cardiac tissue. Additionally, these in vivo experiments have proven the 
epicardial suturing of a strong magnet to be safe and feasible to translate towards clinical 
use. With the joint properties of producing T1-weighted MRI contrast and magnetically 
improving cell retention, the GNTs are conceived to be the first T1-weighted MRI 
intracellular theranostic agent, which can be used to augment the efficacies of stem cell-
based cardiomyoplasty and other cell therapies for the treatment of human diseases. 
 
6.2. Future Work 
6.2.1. Cell Labeling 
The intracellular mechanisms of GNT uptake and eventual release need to be 
elucidated. Although it has established that GNTs readily internalize into MSCs and are 
retained up to 72 h, more work needs to be performed to determine the exact type of 
endocytic and exocytic pathways employed. Additionally, it would be interesting to 
observe the intercellular distribution of GNTs during cell division. Kim et al. noted that 
polystyrene nanoparticles are not expelled from cells but are rather divided between 
daughter cells when the parent cell divides, eventually leading to the dilution of the 
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nanoparticles over several cycles of cell division.
86
 It would be interesting to determine 
whether GNTs follow a similar dilution fate, which would impact the long-term MRI 
visualization of daughter cells, as described below.  
 
6.2.2. Cellular MRI 
A recent study by Tang et al. noted that GNTs exhibited a decrease in T1 
enhancement and an increase in T2 and T2* performance when internalized into 
macrophages.
44
 The authors postulated that this phenomenon can be attributed to the 
slower water exchange rate within cells, the high-density intracellular 
compartmentalization of GNTs, and the possible susceptibility effects produced by the 
residual catalyst impurities remaining from their SWNT precursors, which have also been 
shown to be T2-weighted agents.
87
  
 After observing the dense intracellular GNT aggregation from the TEM images in 
Figure 3.2, it is expected that GNT-labeled MSCs should also exhibit a reduction in T1 
enhancement, which was evidenced by only a two-fold decrease in T1 relaxation time 
when imaging cells in a 1.5 T clinical MRI scanner.  It is also anticipated that the large 
GNT aggregates could also amplify the T2/T2* performance of the GNTs; therefore, a 
comprehensive T2-weighted imaging study should be completed to observe this effect. 
Another interesting approach would be to examine the dependence of T1 and T2 
performance on intracellular GNT aggregation and to perform a time-dependent MR 
imaging study of MSCs internalizing GNTs. Assuming that the water exchange dynamics 
is faster and GNT aggregation is lower outside of cells, the T1 performance of the GNTs 
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should be higher when residing extracellularly; in contrast, T2 enhancement dominates 
intracellularly due to the slower water dynamics and the existence of dense GNT 
aggregates. Therefore, it is expected that diminished T1 performance and a respective 
increase in T2 enhancement should be observed as GNTs are gradually internalized by 
MSCs. The opposite result is expected if GNTs are diluted through several cell divisions, 
allowing for T1 to dominate for daughter cells.   
 
6.2.3. Cellular Response 
Although Chapter 4 primarily focused on the changes in cell cycle mechanisms of 
GNT-labeled MSCs, the information collected by the completed transcriptome analysis, 
which detected over 130 genetic changes, can spawn several future studies that detail the 
downstream outcome of intracellular GNT incorporation.  Other cellular pathways of 
interest include cellular adhesion behavior, endocytic and exocytic mechanisms, and 
immune response to GNTs. In addition to adding more test samples to demonstrate 
statistical significance for the genetic profiling of GNT-labeled MSCs, more work 
analyzing the cell proliferation and adhesion behavior of GNT-labeled MSCs over longer 
periods of time is needed to determine whether GNT-labeled MSCs fully recover from 
the mild effects experienced by the cells after GNT incorporation. 
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6.2.4. Magnetic Retention of Cells 
In addition to the future work discussed at the end of Chapter 5, it is suggested to 
repeat all magnetic retention studies using GNT-labeled MSCs that have been labeled 48 
h prior to cell injection. As described in the previous studies, GNT-labeled MSCs that 
have been cultured for 48 h recover from their transient growth lag phase and regain their 
cell adhesion properties, while retaining the same amount of GNTs as from the time of 
cell labeling. The recovery of normal cell growth and adhesion may be critical for 
increasing the chances of cell survival and engraftment after transplantation, which in 
turn may lead to a more positive therapeutic outcome. 
To fully realize the theranostic potential of the GNTs for cellular 
cardiomyoplasty, all future in vivo experiments should be interfaced with concurrent MRI 
tracking studies of the engrafted cells within the animal models. Rather than performing 
elemental analyses of extracted tissues, MRI visualization will be preferred in the clinical 
setting as a noninvasive method to help quantify the retention and survival of 
transplanted GNT-labeled MSCs in the heart. Both T1- and T2- weighted imaging of the 
GNT-labeled MSCs should be performed, and long-term studies should be completed to 
assess MSC integration into cardiac tissue and functional improvement of the heart. 
Another innovative study that can be explored using the magnetic properties of 
GNT-labeled MSCs is the magnetically-guided construction of three-dimensional cell 
constructs for tissue engineering. Magnetically guiding cell growth can lead to tubular 
construction for angiogenesis, 3D patches for cell implantation, and the formation of 
other complex structures for organ development.   
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Appendix A 
Figure A1. Light microscopy images of GNT-labeled MSCs at each step of the cell 
cleaning protocol. Scale bar = 50 µm. 
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Figure A2. Cell viability analysis performed on GNT-labeled MSCs using a 
LIVE/DEAD viability/toxicity assay kit. Fluorescence-activated cell sorting (8580 
gated events) was used to measure the fluorescence intensities for calcein AM (Calc, 
detection of live cells) and ethidium homodimer-1 (EthD, detection of dead cells). 
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Appendix B 
Heat maps containing the 123 differentially expressed transcripts analyzed from the 
transcriptome analysis of GNT-labeled MSCs (columns 1-3) and unlabeled MSCs 
(columns 4-6). Note: some transcripts may be duplicated/triplicated in the maps. 
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Appendix C 
Cell cycle (6) and immune response pathway analysis (6) maps affected by GNT 
incorporation into MSCs.  
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Appendix D 
Cell cycle genes affected by GNT incorporation into MSCs. 
    
Gene Gene Function 
BIRC5 Required for chromosome segregation and cytokinesis (also known as Survivin)88 
CCDC99 Required for the localization of dynein and dynactin to the mitotic kinetochore89 
CDC45 Required to the initiation of DNA replication90 
CDCA3 Required for entry into mitosis and acts by participating at G2/M phase (also known as 
Tome-1)91 
CHAF-1 Facilitates DNA methylation and histone H3 'Lys-9' methylation during replication-
coupled chromatin assembly92 
CKS2 Binds to the catalytic subunit of the cyclin dependent kinases and is essential for 
transitions between the G1/S phases and the G2/M phases93 
Condensin Required for conversion of interphase chromatin into mitotic-like condense 
chromosomes94 
Cyclin B1 and B2 Components of cell cycle regulatory machinery, expressed during G2/M phase95 
Cyclin G2 Negative regulator of cell cycle progesssion96 
E2F1 Transcription activator of genes encoding proteins involved in DNA replication and cell-
cycle progression from G1 to S phase97 
FBox5 Regulates progression through early mitosis by inhibiting the anaphase promoting 
complex/cyclosome (APC)98 
FEN1 5'-flap endonuclease and 5'-3' exonuclease involved in DNA replication99 
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GINS1 Required both for the initiation of chromosome replication and also for the normal 
progression of DNA replication forks (also known as PSF1)100  
INCENP Component of the chromosomal passenger complex (CPC), a complex that acts as a key 
regulator of mitosis and required for metato-anaphase transition101 
KIF23 Moves antiparallel microtubules and localizes to the interzone of mitotic spindles102 
MCM 2 and 4 Required for the initiation of eukaryotic genome replication103 
MIS18 Required for normal chromosome segregation during mitosis104 
PCNA Involved in the control of eukaryotic DNA replication105 
PLK4 Required for centriole duplication106 
PRC1 Cross-links antiparallel microtubules; involved in cytokinesis107 
RCS1 Mitotic regulator that controls the metaphase-to-anaphase transition108 
SKA1 and 2 Required for timely anaphase onset during mitosis109 
TCF19 Inhibits cell cycle by transcriptional repression of Cyclin E110 
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Appendix E 
Figure D1. Flow cytometry diagrams of cell cycle analysis for Pig 1. 
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Figure D2. Flow cytometry diagrams of cell cycle analysis for Pig 2. 
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Figure D3. Flow cytometry diagrams of cell cycle analysis for Pig 3.  
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